Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance.
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The effect of graded, physiologic hyperinsulinemia (+5, +15, +30, +70, +200 microU/ml) on oxidative and nonoxidative pathways of glucose and FFA metabolism was examined in nine lean non-insulin dependent diabetic patients (NIDDM) and in eight age- and weight-matched control subjects. Glucose and FFA metabolism were assessed using stepwise insulin clamp in combination with indirect calorimetry and infusion of [3H]3-glucose/[14C]palmitate. The basal rate of hepatic glucose production (HGP) was higher in NIDDM than in control subjects, and suppression of HGP by insulin was impaired at all but the highest insulin concentration. Glucose disposal was reduced in the NIDD patients at the three highest plasma insulin concentrations, and this was accounted for by defects in both glucose oxidation and nonoxidative glucose metabolism. In NIDDs, suppression of plasma FFA by insulin was impaired at all five insulin steps. This was associated with impaired suppression by insulin of plasma FFA turnover, FFA oxidation (measured by [14C]palmitate) and nonoxidative FFA disposal (an estimate of reesterification of FFA). FFA oxidation and net lipid oxidation (measured by indirect calorimetry) correlated positively with the rate of HGP in the basal state and during the insulin clamp. In conclusion, our findings demonstrate that insulin resistance is a general characteristic of glucose and FFA metabolism in NIDDM, and involves both oxidative and nonoxidative pathways. The data also demonstrate that FFA/lipid and glucose metabolism are interrelated in NIDDM, and suggest that an increased rate of FFA/lipid oxidation may contribute to the impaired suppression of HGP and diminished stimulation of glucose oxidation by insulin in these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Plasma insulin concentrations such as those observed during the present insulin/glucose or glucose infusion studies, are known to completely suppress hepatic glucose production (27); thus, under these conditions, total glucose uptake is equal to exogenous glucose infusion.”
From Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans (1993) · cites this paper as [27]
In the citing paper
“Notably, insulin resistance is also associated with a decreased ability to suppress lipolysis in adipose tissue and altered fatty acid oxidation.50,51”
From The effects of sleep disruption on metabolism, hunger, and satiety, and the influence of psychosocial stress and exercise: A narrative review (2024) · cites this paper as [51]
In the citing paper
“In lean healthy individuals insulin stimulates glucose uptake into skeletal muscle in a dose-dependent manner, with a half-maximal effect (EC50) at a plasma insulin concentration ~60 μU/mL [21].”
From Pathogenesis of insulin resistance in skeletal muscle (2010) · cites this paper as [21]
In the citing paper
“Using the gold standard euglycemic hyperinsulinemic clamp technique to quantify insulin-stimulated glucose uptake, they demonstrated that both lean and obese T2DM subjects have marked decrease (>50%) in whole body glucose disposal during the insulin clamp.”
From Pathogenesis of insulin resistance in skeletal muscle (2010) · cites this paper as [21]
In the citing paper
“During the postabsorptive state, the plasma insulin concentration is low. Since the plasma insulin concentration is the principal factor that restrains lipolysis in adipocytes [21] and stimulates glucose uptake in skeletal muscle [21], during the fasting state, muscle glucose uptake is low and the plasma FFA concentration is elevated.”
From Pathogenesis of insulin resistance in skeletal muscle (2010) · cites this paper as [21]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Self-citationRandle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093 · cited 2×
“More than 20 years ago Randle and co-workers introduced the concept of substrate competition, whereby enhanced availability and oxidation of FFA leads to an impairment in glucose oxidation (17).”
BackgroundImmunoassay of insulin with insulin-antibody precipitate
HALES, C., & RANDLE, P. (1963) · Biochemical Journal · doi:10.1042/bj0880137 · Cited by 2,638
The theoretical bases of indirect calorimetry: A review
Ferrannini, E. (1988) · Metabolism · doi:10.1016/0026-0495(88)90110-2 · Cited by 1,580
Self-citationRegulation of hepatic fatty acid oxidation and ketone body production
McGarry, J. D., & Foster, D. W. (1980) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.49.070180.002143 · Cited by 1,460 · cited 1×
“Since CPT I is inhibited by both insulin and malonyl-CoA, which is generated by condensation of acetyl-CoA (56), the insulin-mediated decline in FFA oxidation could have been due to a direct effect of the hormone on CPT I.”
BackgroundRelationship Between Carbohydrate and Lipid Metabolism and the Energy Balance of Heart Muscle
Neely, J. R., & Morgan, H. E. (1974) · Annual Review of Physiology · doi:10.1146/annurev.ph.36.030174.002213 · Cited by 1,261
DeFronzo, R. A., Gunnarsson, R., Björkman, O., Olsson, M., & Wahren, J. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111938 · Cited by 1,167 · cited 2×
“in insulin-mediated glucose metabolism affects both hepatic and peripheral tissues, primarily muscle (1-6).”
BackgroundSelf-citationEffect of fatty acids on glucose production and utilization in man.
Ferrannini, E., Barrett, E. J., Bevilacqua, S., & DeFronzo, R. A. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111133 · Cited by 1,050
Self-citationRadioimmunological determination of human C-peptide in serum
Heding, L. G. (1975) · Diabetologia · doi:10.1007/bf01222104 · Cited by 830
Kolterman, O. G., Gray, R. S., Griffin, J., Burstein, P., Insel, J., Scarlett, J. A., & Olefsky, J. M. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110350 · Cited by 629
Cited by
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
“(26) demonstrated that the antilipolytic effect of insulin was markedly impaired in lean type 2 diabetic subjects, as well as in obese nondiabetic subjects (140).”
BackgroundMethodInfluentialSelf-citationDeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationMuniyappa, R., Lee, S., Chen, H., & Quon, M. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00645.2007 · Cited by 1,643
“Similarly, radiolabeled tracers of glycerol or amino acids may be used during the glucose clamp to assess insulin sensitivity with respect to lipolysis or protein metabolism (42, 44).”
MethodPathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
“7) [1,2,12,114].”
InfluentialSelf-citationLewis, G. F., Carpentier, A., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,333
“A number of studies have shown a diminished suppressive effect of insulin on FFA rate of appearance in obese and nonobese insulin-resistant humans (20, 21, 29) and in those with type 2 diabetes (25, 30).”
BackgroundPharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
“Bedtime insulin takes advantage of the differential sensitivity of hepatic compared with peripheral tissues to insulin (7, 9).”
BackgroundSelf-citationAMP-activated protein kinase signaling in metabolic regulation
Long, Y. C. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29044 · Cited by 1,098
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Metabolic Flexibility in Health and Disease
Goodpaster, B. H., & Sparks, L. M. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.015 · Cited by 995
“In the contrasting diabetic state, the amount of insulin required to completely sup- press hepatic glucose production only achieves an 85% suppression of adipose lipolysis (Groop et al., 1989).”
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity
Fabbrini, E., Magkos, F., Mohammed, B. S., Pietka, T., Abumrad, N. A., Patterson, B. W., Okunade, A., & Klein, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904944106 · Cited by 972
“These two insulin infusion rates were chosen to evaluate adipose tissue insulin sensitivity (low-dose insulin infusion to submaximally suppress adipose tissue lipolysis) and skeletal muscle insulin sensitivity (high-dose insulin infusion to stimulate muscle glucose uptake) (38).”
MethodWhy does obesity cause diabetes?
Klein, S., Gastaldelli, A., Yki-Järvinen, H., & Scherer, P. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.012 · Cited by 939
“However, increased hepatic glucose production occurs when the increased secretion of insulin is not adequate to compensate for insulin resistance as in people with impaired fasting glucose or when the secretion of insulin decreases as in people with type 2 diabetes (Groop et al., 1989; Natali et al., 2000).”
BackgroundHyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome
Ferrannini, E., Haffner, S. M., Mitchell, B. D., & Stern, M. P. (1991) · Diabetologia · doi:10.1007/bf00403180 · Cited by 898
“Previous studies using the euglycaemic insulin clamp technique [25] have shown that insulin resistance is present in non-diabetic, normotensive obese subjects [26], in lean, normotensive patients with Type 2 diabetes [27] or impaired glucose tolerance [28, 29], in lean, normotensive hypertriglyceridaemic subjects [30]…”
Self-citationFatty acids, obesity, and insulin resistance: Time for a reevaluation
Karpe, F., Dickmann, J. R., & Frayn, K. N. (2011) · Diabetes · doi:10.2337/db11-0425 · Cited by 896
“The rationale for this supposition comes from the fact that adipose tissue could be seen as insulin resistant in obesity and therefore as not responding adequately to the antilipolytic action of insulin (29).”
BackgroundPeters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citationBugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., Ponti, V., Pagano, G., Ferrannini, E., & Rizzetto, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1682-x · Cited by 770
“Furthermore, in this condition, hepatic insulin resistance is usually more severe and results in absolute glucose overproduction [52].”
BackgroundSelf-citationAdipose tissue as a buffer for daily lipid flux
Frayn, K. (2002) · Diabetologia · doi:10.1007/s00125-002-0873-y · Cited by 752
“The ability of insulin to suppress fatty acid release is impaired in obesity and other insulin-resistant states [19, 44, 45, 46, 47, 48].”
BackgroundAitman, T. J., Glazier, A. M., Wallace, C. A., Cooper, L. D., Norsworthy, P. J., Wahid, F. N., Al-Majali, K. M., Trembling, P. M., Mann, C. J., Shoulders, C. C., et al. (1999) · Nature Genetics · doi:10.1038/5013 · Cited by 735
Management of Hyperglycemic Crises in Patients With Diabetes
Kitabchi, A. E., Umpierrez, G. E., Murphy, M. B., Barrett, E. J., Kreisberg, R. A., Malone, J. I., & Wall, B. M. (2001) · Diabetes Care · doi:10.2337/diacare.24.1.131 · Cited by 710
Pathogenesis of insulin resistance in skeletal muscle
Abdul-Ghani, M. A., & DeFronzo, R. A. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/476279 · Cited by 670
“In insulin resistant individuals, for example, nondiabetic obese and lean type 2 diabetic subjects, the ability of insulin to inhibit lipolysis and reduce plasma FFA concentration is markedly impaired [21, 59], leading to an increased rate of lipolysis and chronic elevation in the plasma FFA concentration.”
BackgroundInfluentialSelf-citationBays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
Self-citationGastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629
Exercise and Insulin Sensitivity: A Review
Borghouts, L. B., & Keizer, H. A. (2000) · International Journal of Sports Medicine · doi:10.1055/s-2000-8847 · Cited by 597
Korenblat, K. M., Fabbrini, E., Mohammed, B. S., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.075 · Cited by 592
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540
Self-citationThe Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis
Saponaro, C., Gaggini, M., Carli, F., & Gastaldelli, A. (2015) · Nutrients · doi:10.3390/nu7115475 · Cited by 529
“As insulin concentration increases, lipolysis, and thus plasma free fatty acids (FFA) concentration, is suppressed following a non-linear curve [65,69,70].”
BackgroundInfluentialHow to measure insulin sensitivity
Ferrannini, E., & Mari, A. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816070-00001 · Cited by 512
Self-citationKashyap, S., Belfort, R., Gastaldelli, A., Pratipanawatr, T., Berria, R., Pratipanawatr, W., Bajaj, M., Mandarino, L., DeFronzo, R., & Cusi, K. (2003) · Diabetes · doi:10.2337/diabetes.52.10.2461 · Cited by 503
Self-citationImpaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus.
Kelley, D. E., & Simoneau, J. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117600 · Cited by 487
Obesity-related non-communicable diseases: South Asians vs White Caucasians
Misra, A., & Khurana, L. (2011) · International Journal of Obesity · doi:10.1038/ijo.2010.135 · Cited by 469
The impact of insulin resistance on the kidney and vasculature
Artunc, F., Schleicher, E., Weigert, C., Fritsche, A., Stefan, N., & Häring, H.-U. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.145 · Cited by 462
Lomonaco, R., Ortiz-Lopez, C., Orsak, B., Webb, A., Hardies, J., Darland, C., Finch, J., Gastaldelli, A., Harrison, S., Tio, F., et al. (2012) · Hepatology · doi:10.1002/hep.25539 · Cited by 459
Determination of confidence intervals of metabolic fluxes estimated from stable isotope measurements
Antoniewicz, M. R., Kelleher, J. K., & Stephanopoulos, G. (2006) · Metabolic Engineering · doi:10.1016/j.ymben.2006.01.004 · Cited by 449
Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction
Kirk, E., Reeds, D. N., Finck, B. N., Mayurranjan, M. S., Patterson, B. W., & Klein, S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.048 · Cited by 440
Pathogenesis of Type 2 (non-insulin dependent) diabetes mellitus: a balanced overview
DeFronzo, R. A. (1992) · Diabetologia · doi:10.1007/bf00401208 · Cited by 430
“This paradox is explained by the distinctive dose-response relationships between plasma insulin concentration vs hepatic glucose production and tissue glucose disposal [29, 33-35 ].”
InfluentialSelf-citationSteven, S., Hollingsworth, K. G., Al-Mrabeh, A., Avery, L., Aribisala, B., Caslake, M., & Taylor, R. (2016) · Diabetes Care · doi:10.2337/dc15-1942 · Cited by 418
Jung, U. J., Lee, M.-K., Park, Y. B., Kang, M. A., & Choi, M.-S. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.12.002 · Cited by 414
In vivo regulation of lipolysis in humans.
Coppack, S. W., Jensen, M. D., & Miles, J. M. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41207-6 · Cited by 407
Dose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling
Belfort, R., Mandarino, L., Kashyap, S., Wirfel, K., Pratipanawatr, T., Berria, R., DeFronzo, R. A., & Cusi, K. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1640 · Cited by 404
Self-citationKars, M., Yang, L., Gregor, M. F., Mohammed, B. S., Pietka, T. A., Finck, B. N., Patterson, B. W., Horton, J. D., Mittendorfer, B., Hotamisligil, G. S., et al. (2010) · Diabetes · doi:10.2337/db10-0308 · Cited by 400
“infusion to stimulate muscle glucose uptake) (27).”
Hong, S.-H., & Choi, K. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020494 · Cited by 390
“Imported glucose is stored as glycogen or enters the glycolytic pathway, and is either oxidized or released as lactate [52].”
BackgroundChavez, A. O., Molina-Carrion, M., Abdul-Ghani, M. A., Folli, F., DeFronzo, R. A., & Tripathy, D. (2009) · Diabetes Care · doi:10.2337/dc09-0684 · Cited by 390
“Tritiated glucose specific activity was determined on deproteinized plasma samples as previously described (19).”
MethodSelf-citationDiabetes mellitus: complications and therapeutics.
Tripathi, B. K., & Srivastava, A. K. (2006) · PubMed · Cited by 493
Pathophysiology and Pharmacological Treatment of Insulin Resistance*
Matthaei, S., Stumvoll, M., Kellerer, M., & Häring, H.-U. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0413 · Cited by 377
“In obese subjects and patients with type 2 diabetes the EC50 values are increased 2- to 3-fold (44, 47, 49), indicating that adipose tissue lipolysis is at least as resistant to the action of insulin as muscle and liver.”
BackgroundInsulin action and insulin resistance in human skeletal muscle
Zierath, J. R., Krook, A., & Wallberg-Henriksson, H. (2000) · Diabetologia · doi:10.1007/s001250051457 · Cited by 367
“From in vivo tracer studies, the defect in wholebody glucose uptake in Type II diabetic patients has been localised to the non-oxidative pathway for glucose metabolism [8, 13, 15, 16].”
BackgroundBajaj, M., Suraamornkul, S., Piper, P., Hardies, L. J., Glass, L., Cersosimo, E., Pratipanawatr, T., Miyazaki, Y., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031315 · Cited by 358
“Tritiated glucose-specific activity was determined on deproteinized barium/zinc plasma samples as previously described (28).”
MethodSelf-citationInsulin Resistance Early in Adulthood in Subjects Born with Intrauterine Growth Retardation1
Jaquet, D., Gaboriau, A., Czernichow, P., & Levy-Marchal, C. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.4.6544 · Cited by 347
“We thus made the assumption that hepatic glucose production would be suppressed by the insulin infusion rate used during the clamps in IUGR subjects with normal glucose tolerance, as reported in normal glucose-tolerant subjects (14).”
BackgroundEffects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes.
Boden, G., & Chen, X. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118160 · Cited by 344
Gastaldelli, A., Gaggini, M., & DeFronzo, R. A. (2017) · Diabetes · doi:10.2337/db16-1167 · Cited by 344
“In contrast to the OGTT, studies with the stepped hyperinsulinemic clamp consistently have demonstrated impaired suppression of plasma FFA and glycerol concentrations and (14)C-palmitate turnover (18,22,24) (i.”
BackgroundMethodResultInfluentialSelf-citationBeta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2004) · Diabetologia · doi:10.1007/s00125-003-1263-9 · Cited by 338
Self-citationWoodman, R. J., Mori, T. A., Burke, V., Puddey, I. B., Watts, G. F., & Beilin, L. J. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.5.1007 · Cited by 338
“The consequent decrease in free fatty acid availability would lead to decreased triacylglycerol synthesis, and an increase in hepatic free fatty acid oxidation could both increase hepatic gluconeogenesis (46) and decrease glucose oxidation via the Randle glucose–fatty acid cycle (47).”
BackgroundKotronen, A., Juurinen, L., Tiikkainen, M., Vehkavaara, S., & Yki–Järvinen, H. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.021 · Cited by 339
Insulin: The master regulator of glucose metabolism
Norton, L., Shannon, C., Gastaldelli, A., & DeFronzo, R. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155142 · Cited by 330
Self-citationMolecular pathophysiology of hepatic glucose production
Sharabi, K., Tavares, C. D. J., Rines, A. K., & Puigserver, P. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.09.003 · Cited by 325
“Insulin resistance—The resistance to insulin's action is characteristic of both lean and obese diabetic patients as well as diabetic rodent models (DeFronzo et al., 1985; Groop et al., 1989; Koranyi et al., 1990), and is considered the main driver of T2DM.”
Vollenweider, P., Tappy, L., Randin, D., Schneiter, P., Jéquier, E., Nicod, P., & Scherrer, U. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116542 · Cited by 321
DeFronzo, R. A., & Abdul-Ghani, M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.013 · Cited by 317
Self-citationPathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
“in 2,3,8,40), including impaired glucose transport/phosphorylation (17), reduced glycogen synthesis (39), and decreased glucose oxidation (17).”
BackgroundMethodInfluentialSelf-citationGlucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo.
Nuutila, P., Koivisto, V. A., Knuuti, J., Ruotsalainen, U., Teräs, M., Haaparanta, M., Bergman, J., Solin, O., Voipio-Pulkki, L. M., & Wegelius, U. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115780 · Cited by 313
“Since skeletal muscle is responsible for the majority of diminished glucose uptake in various insulin-resistant states (13, 14), which also are characterized by abnormalities in FFA metabolism (15, 16), it is of interest to determine whether the glucose-FFA cycle operates in this tissue in man.”
BackgroundGROOP, L. C., SALORANTA, C., SHANK, M., BONADONNA, R. C., FERRANNINI, E., & DEFRONZO, R. A. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-96 · Cited by 312
Self-citationRoden, M., Stingl, H., Chandramouli, V, Schumann, W. C., Hofer, A., Landau, B. R., Nowotny, P., Waldhäusl, W., & Shulman, G. I. (2000) · Diabetes · doi:10.2337/diabetes.49.5.701 · Cited by 288
“5-fold higher in the portal than the peripheral vein (36), which could attenuate EGP (37) by a decrease in GNG or, more likely, in hepatic glycogenolysis (38,39).”
BackgroundBajaj, M., Suraamornkul, S., Pratipanawatr, T., Hardies, L. J., Pratipanawatr, W., Glass, L., Cersosimo, E., Miyazaki, Y., & DeFronzo, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1364 · Cited by 290
“Tritiated glucose specific activity was determined on deproteinized barium/zinc plasma samples as previously described (15).”
MethodSelf-citationRebrin, K., Steil, G. M., Mittelman, S. D., & Bergman, R. N. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118846 · Cited by 289
“Several studies have shown NIDDM subjects to be resistant to FFA suppression by insulin (43–46), and evidence exists for both an increase in lipolysis (30) and a decrease in reesterification (47).”
BackgroundInfluentialGastaldelli, A., Harrison, S. A., Belfort-Aguilar, R., Hardies, L. J., Balas, B., Schenker, S., & Cusi, K. (2009) · Hepatology · doi:10.1002/hep.23116 · Cited by 285
Saturated FFAs, Palmitic Acid and Stearic Acid, Induce Apoptosis in Human Granulosa Cells
Mu, Y.-M., Yanase, T., Nishi, Y., Tanaka, A., Saito, M., Jin, C., Mukasa, C., Okabe, T., Nomura, M., Goto, K., et al. (2001) · Endocrinology · doi:10.1210/en.142.8.3590 · Cited by 276
The adipocyte as an endocrine organ in the regulation of metabolic homeostasis
Harwood, H. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.010 · Cited by 273
“This increased hepatic FFA delivery is likely responsible for the increased gluconeogenesis and VLDL production by the liver (Groop et al., 1989).”
BackgroundReducing insulin resistance with metformin: the evidence today
Giannarelli, R., Aragona, M., Coppelli, A., & Del Prato, S. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(03)72785-2 · Cited by 269
“In the adipose tissue, impairment of insulin-mediated glucose- and lipid metabolism results in accelerated lipolysis and increased free-fatty acid (FFA) release [16].”
BackgroundRizkalla, S. W., Taghrid, L., Laromiguiere, M., Huet, D., Boillot, J., Rigoir, A., Elgrably, F., & Slama, G. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1866 · Cited by 263
“During the infusion of this high insulin dose of 6 mU kg 1 min (1), hepatic glucose production was supposed to be zero (19), so that the exogenous glucose infusion provides a measurement of the total-body glucose disposal.”
BackgroundRegulation of fatty acid synthase (FAS)
Semenkovich, C. F. (1997) · Progress in Lipid Research · doi:10.1016/s0163-7827(97)00003-9 · Cited by 264
Perseghin, G., Caumo, A., Caloni, M., Testolin, G., & Luzi, L. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.10.7902 · Cited by 259
“In fact, it has been observed that obese patients with type 2 diabetes mellitus have impaired regulation of lypolisis (23, 24), and that in vivo experimental increments of plasma FFA concentrations in healthy humans can induce an IR similar to that observed in type 2 diabetes (25, 26).”
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
“leading to accelerated lipolysis and elevated circulating free fatty acid (FFA) levels.(11) Increased plasma FFA,(12,13) in concert with in-”
BackgroundSelf-citationOrtiz-Lopez, C., Lomonaco, R., Orsak, B., Finch, J., Chang, Z., Kochunov, V. G., Hardies, J., & Cusi, K. (2012) · Diabetes Care · doi:10.2337/dc11-1849 · Cited by 253
“Insulin is also a strong inhibitor of lipolysis, and a similar relationship exists in healthy subjects between the FPI concentration and fasting plasma FFA levels (17).”
BackgroundAbdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus
Miyazaki, Y., Glass, L., Triplitt, C., Wajcberg, E., Mandarino, L. J., & DeFronzo, R. A. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.0327.2001 · Cited by 251
“The hepatic insulin resistance index correlated with VF (r 0.39, P 0.01), SF (r 0.34, P 0.01), and DSF (r 0.41, P 0.01), but not with SSF. VF also was correlated with the EGP/ insulin during the 40 mU m 2 min 1 insulin clamp step (r 0.35, P 0.01).”
BackgroundInfluentialSelf-citationHow can we measure insulin sensitivity/resistance?
Antuna-Puente, B., Disse, E., Rabasa-Lhoret, R., Laville, M., Capeau, J., & Bastard, J.-P. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.01.002 · Cited by 250
Measuring and estimating insulin resistance in clinical and research settings
Gastaldelli, A. (2022) · Obesity · doi:10.1002/oby.23503 · Cited by 244
“Insulin concentration is expected to rise almost 10 times during a 40 mU/min m(2) clamp (from 6 1 to 75 5 mU/L and from 7 1 to 82 5 mU/L in healthy participants without obesity and participants with diabetes, respectively [4]).”
BackgroundMethodInfluentialSchwarz, J. M., Neese, R. A., Turner, S., Dare, D., & Hellerstein, M. K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118342 · Cited by 244
“Accordingly, lipolysis and fat oxidation tend to be increased rather than suppressed in the insulin resistance associated with obesity (36, 37).”
BackgroundBalas, B., Baig, M. R., Watson, C., Dunning, B. E., Ligueros-Saylan, M., Wang, Y., He, Y.-L., Darland, C., Holst, J. J., Deacon, C. F., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1882 · Cited by 243
Self-citationDimitriadis, G. D., Maratou, E., Kountouri, A., Board, M., & Lambadiari, V. (2021) · Nutrients · doi:10.3390/nu13010159 · Cited by 241
“The decrease in NEFA levels is of major importance since it mediates the suppression of endogenous glucose production in the liver/kidney and the increase in the rates of glucose utilization in muscle [20,21].”
BackgroundPatel, T. P., Rawal, K., Bagchi, A. K., Akolkar, G., Bernardes, N., Dias, D. D. S., Gupta, S., & Singal, P. K. (2016) · Heart Failure Reviews · doi:10.1007/s10741-015-9515-6 · Cited by 240
Dysfunctional fat cells, lipotoxicity and type 2 diabetes
Defronzo, R. A. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2004.00389.x · Cited by 236
Self-citationGroop, L., Ekstrand, A., Forsblom, C., Wid�n, E., Groop, P. H., Teppo, A. M., & Eriksson, J. (1993) · Diabetologia · doi:10.1007/bf00404074 · Cited by 234
“Insulin resistance has been considered a characteristic feature of both hypertension and Type 2 diabetes [1-5, 19], and the hypertensive Type 2 diabetic patients of the current study showed a more severe defect in their glucose metabolism than normotensive patients.”
BackgroundSelf-citationDiabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo
Williams, K. H., Shackel, N. A., Gorrell, M. D., McLennan, S. V., & Twigg, S. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1009 · Cited by 233
Miyazaki, Y., Mahankali, A., Wajcberg, E., Bajaj, M., Mandarino, L. J., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0190 · Cited by 227
Self-citationO’Gorman, D. J., Karlsson, H. K. R., McQuaid, S., Yousif, O., Rahman, Y., Gasparro, D., Glund, S., Chibalin, A. V., Zierath, J. R., & Nolan, J. J. (2006) · Diabetologia · doi:10.1007/s00125-006-0457-3 · Cited by 226
“Defects in whole-body insulin-mediated glucose uptake in type 2 diabetic patients have been tracked to impairments in insulin signalling and GLUT4 (now known as solute carrier family 2 [facilitated glucose transporter], member 4 [SLC2A4]) translocation [6–8].”
BackgroundGlitazones: clinical effects and molecular mechanisms
Stümvoll, M., & Häring, H. (2002) · Annals of Medicine · doi:10.1080/713782132 · Cited by 225
“In patients with type 2 diabetes impaired insulin suppression of lipolysis has been reported (3).”
BackgroundPioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M., & Nissen, S. E. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118825376 · Cited by 223
Self-citationPhasic Insulin Release and Metabolic Regulation in Type 2 Diabetes
Del Prato, S., Marchetti, P., & Bonadonna, R. C. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s109 · Cited by 223
“In contrast, a similar inhibition of hepatic glucose production in type 2 diabetic patients was reached only with a much greater increment in the portal levels of insulin (27).”
BackgroundInfluentialSelf-citationRosso, C., Kazankov, K., Younes, R., Esmaili, S., Marietti, M., Sacco, M., Carli, F., Gaggini, M., Salomone, F., Møller, H. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.031 · Cited by 217
Zierler, K. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.3.e409 · Cited by 217
“Resistance to insulin in patients with NIDDM has been associated with high plasma FFA concentration (51).”
BackgroundCatecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity
Jocken, J. W. E., & Blaak, E. E. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.01.002 · Cited by 209
Campbell, P. J., Carlson, M. G., Hill, J. O., & Nurjhan, N. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2006.263.6.e1063 · Cited by 207
“Secondary FFA reesterification is calculated as FFA R, minus FFA oxidation (6, 16-18, 24, 31).”
MethodResultInfluentialTripathy, D., Almgren, P., Tuomi, T., & Groop, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.9.2204 · Cited by 205
“Because the EGP is extremely sensitive to the fasting insulin concentrations (24,25), we determined the hepatic insulin sensitivity by dividing the basal EGP rates by the fasting insulin concentration (25).”
MethodSelf-citationThioredoxin-interacting Protein (Txnip) Is a Critical Regulator of Hepatic Glucose Production
Chutkow, W. A., Patwari, P., Yoshioka, J., & Lee, R. T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708169200 · Cited by 204
How to Measure Adipose Tissue Insulin Sensitivity
Søndergaard, E., Espinosa De Ycaza, A. E., Morgan-Bathke, M., & Jensen, M. D. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00047 · Cited by 198
Thiazolidinediones improve β-cell function in type 2 diabetic patients
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00551.2006 · Cited by 200
Self-citationGlucose fatty acid interactions and the regulation of glucose disposal
Randle, P. J., Priestman, D. A., Mistry, S. C., & Halsall, A. (1994) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240550002 · Cited by 199
Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance
Hernández, E. Á., Kahl, S., Seelig, A., Begovatz, P., Irmler, M., Kupriyanova, Y., Nowotny, B., Nowotny, P., Herder, C., Barosa, C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89444 · Cited by 194
Nurjhan, N., Consoli, A., & Gerich, J. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115558 · Cited by 195
Daily magnesium supplements improve glucose handling in elderly subjects
Paolisso, G., Sgambato, S., Gambardella, A., Pizza, G., Tesauro, P., Varricchio, M., & D'Onofrio, F. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/55.6.1161 · Cited by 194
Combination therapy with GLP ‐1 receptor agonist and SGLT2 inhibitor
DeFronzo, R. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12982 · Cited by 192
Self-citation
Metadata
- Authors
- Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A.
- Affiliations
- University of Helsinki (FI)
- Venue
- Journal of Clinical Investigation
- Published
- 1989-07-01
- Volume
- 84
- Issue
- 1
- Pages
- 205-213
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC303971
- OpenAlex
- W1981456793
- Cited by
- 812
- References
- 61
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 28 · 2023: 15 · 2022: 27 · 2021: 30 · 2020: 19 · 2019: 17 · 2018: 25 · 2017: 32 · 2016: 26 · 2015: 22 · 2014: 22 · 2013: 26 · 2012: 26
- FWCI
- 16.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- National Institutes of Health (AM 24 092)
- Fogarty International Center (F05-TWO-3451)
- National Center for Research Resources (RR 125)
- Ministero dell'Istruzione e del Merito
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- type 2 diabetes, insulin resistance, glucose metabolism, free fatty acid metabolism, hepatic glucose production, glucose oxidation, nonoxidative glucose metabolism, fatty acid oxidation, fatty acid re-esterification, hyperinsulinemia, insulin clamp, lipid oxidation
- MeSH terms
- Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Fatty Acids, Nonesterified, Female, Glucose, Humans, Insulin, Insulin Resistance, Liver, Male, Middle Aged, Oxidation-Reduction, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.